Sanofi/Regeneron Pharmaceuticals Inc.’s PCSK9 inhibitor Praluent (alirocumab) is quickly catching its likely competitor in Europe. The drug received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) only two months after another PCSK9 inhibitor, Amgen Inc.’s Repatha (evolocumab), was recommended for approval by the European Medicines Agency panel.
CHMP's decision on Praluent was announced July 24; later the same day, FDA announced its approval of the Sanofi/Regeneron drug, making it the first PCSK9 inhibitor cleared
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?